• 1
    Swinkels DW, Janssen MC, Bergmans J, Markx JJ. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 2006; 52: 950968.
  • 2
    Arnold J, Sangwaiya A, Bhatkal B, Arnold A. Defective release of hepcidin not defective synthesis is the primary pathogenic mechanism in HFE-haemochromatosis. Med Hypotheses 2008; 70: 11972000.
  • 3
    Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 2004; 350: 23832397.
  • 4
    Pietrangelo A. Non-HFE hemochromatosis. Semin Liver Dis 2005; 25: 450460.
  • 5
    Piperno A, Sampietro M, Pietrangelo A, Arosio C, Lupica L, Montosi G, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114: 9961002.
  • 6
    Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 2; 341: 755757.
  • 7
    Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 15; 103: 29142919.
  • 8
    Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145: 209223.
  • 9
    Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G––> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 19; 359: 211218.
  • 10
    Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. N Engl J Med 2008; 358: 221230.
  • 11
    Allen KJ, Gurrin LC, Constantine CC, Delatycki MB, Nicoll AJ, McLaren CE, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 17; 358: 221230.
  • 12
    Robson KJ, Merryweather-Clarke AT, Cadet E, Cadet E, Viprakasit V, Zaahl MG, et al. Recent advances in understanding haemochromatosis: a transition state. J Med Genet 2004; 41: 721730.
  • 13
    Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008; 111: 44564462.
  • 14
    Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. HEPATOLOGY 1992; 15: 655659.
  • 15
    Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. HEPATOLOGY 2008; 48: 9911001.
  • 16
    Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 11071119.
  • 17
    Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. HEPATOLOGY 1997; 25: 162166.
  • 18
    Wheeler CJ, Kowdley KV. Hereditary hemochromatosis: a review of the genetics, mechanism, diagnosis, and treatment of iron overload. Compr Ther 2006; 32: 1016.
  • 19
    Franchini M, Veneri D. Recent advances in hereditary hemochromatosis. Ann Hematol 2005; 84: 347352.
  • 20
    Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochromatosis. Crit Rev Clin Lab Sci 2008; 45: 451484.
  • 21
    Altes A, Ruiz A, Martinez C. The relationship between iron overload and clinical characteristics in Spanish cohort of 100 C282Y homozygous hemochromatosis patients. Ann Hematol 2007; 86: 831835.
  • 22
    Hover AR, McDonnell SM, Burke W. Changing the clinical management of hereditary hemochromatosis: translating screening and early case detection strategies into clinical practice. Arch Intern Med 2004; 164: 957961.
  • 23
    Fowler C. Hereditary hemochromatosis: pathophysiology, diagnosis, and management. Crit Care Nurs Clin North Am 2008; 20: 191201.
  • 24
    Jacobs EM, Verbeek AL, Kreeftenberg HG, van Deursen CT, Marx JJ, Stalenhoef AF, et al. Changing aspects of HFE-related hereditary haemochromatosis and endeavors to early diagnosis. Neth J Med 2007; 65: 419424.
  • 25
    Tavill A. American Association for the Study of Liver Diseases Guidelines: diagnosis and management of hemochromatosis. HEPATOLOGY 2001; 33: 13211328.
  • 26
    Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485504.
  • 27
    Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627633.
  • 28
    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20S37.
  • 29
    Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, et al. High prevalence of the His63Asp HFE mutations in Italian patients with porphyria cutanea tarda. HEPATOLOGY 1998; 27: 181184.
  • 30
    Girelli D, Bozzini C, Roetto A, Daraio F, Colombari R, Olivieri O, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122: 12951302.
  • 31
    Pelucchi S, Mariani R, Salvioni A, Bonfadini S, Riva A, Bertola F, et al. Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. Clin Genet 2008; 73: 171178.
  • 32
    Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457458.
  • 33
    Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observations of each patients. II. Analysis and examples. Br J Cancer 1977; 35: 139.
  • 34
    Therneau TM, Grambsch PM. Modeling Survival Data Extending the Cox Model. New York: Springer; 2000.
  • 35
    McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619624.
  • 36
    O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH. Declining prevalence of diabetes mellitus in hereditary hemochromatosis the results in earlier diagnosis. Diabetes Res Clin Pract 2008; 81: 316320.
  • 37
    Powell EE, Ali A, Clouston AD, Dixon J, Lincoln DJ, Fletcher LM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005; 129: 19371943.
  • 38
    De Marco F, Liguori R, Giardina MG, D'Armiento M, Angelucci E, Lucariello A, et al. High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med 2004; 42: 1724.
  • 39
    Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis 2000; 26: 163168.
  • 40
    Hellerbrand C, Bosserhoff AK, Seegers S, Lingner G, Wrede C, Lock G, et al. Mutation analysis of the HFE gene in German hemochromatosis patients and controls using automated SSCP-based capillary electrophoresis and a new PCR-ELISA technique. Scand J Gastroenterol 2001; 36: 12111216.
  • 41
    D'Amelio R, Matricardi PM, Biselli R, Stroffolini T, Mele A, Spada E, et al. Changing epidemiology of hepatitis B in Italy: public health implications. Am J Epidemiol 1992; 135: 10121018.
  • 42
    Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, et al. Changing epidemiology of HCV and HBV infections in northern Italy: a survey in the general population. J Clin Gastroenterol 2008; 42: 527532.
  • 43
    Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997; 58: 486494.
  • 44
    Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology 2008; 134: 348351.
  • 45
    Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. HEPATOLOGY 2001; 33: 647651.
  • 46
    Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 2008; 123: 18831891.